Product
Somatostatin analogues
1 clinical trial
1 indication
Indication
Neuroendocrine TumorsClinical trial
A Randomised Study of Cessation of Somatostatin Analogues After Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (STOPNET)Status: Not yet recruiting, Estimated PCD: 2027-09-01